Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney internationalJan 2028
GLP-1 Research Tracker
Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.
234 studies tracked·6 compounds covered·Updated Jun 2026
Phase 3
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
orforglipron
Lancet (London, England)Dec 2026
Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.
Renal failureDec 2026
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
semaglutidetirzepatide
Journal of medical economicsDec 2026
Bidirectional interplay between the gut microbiota and GLP-1 receptor agonists: towards Microbiome-Mediated therapeutics in type 2 diabetes mellitus.
Journal of diabetes and metabolic disordersJun 2026
Coronary inflammation: Identification, clinical impact and possible therapeutical solutions.
International journal of cardiologyMay 2026
Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.
semaglutide
PharmacotherapyApr 2026
The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention.
Kidney international reportsApr 2026
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients.
PharmacotherapyApr 2026
Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease.
Neurology. GeneticsApr 2026
Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.
semaglutidetirzepatide
Current opinion in cardiologyMar 2026
Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.
tirzepatide
Minerva endocrinologyMar 2026
AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework.
semaglutide
JMIR AIMar 2026
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.
semaglutide
Endocrine connectionsMar 2026
Semaglutide attenuates diabetic vascular calcification by enhancing autophagy and lysosomal function via targeting CPNE1.
semaglutide
Apoptosis : an international journal on programmed cell deathMar 2026
Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.
tirzepatide
The patientMar 2026
Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence.
Diabetes research and clinical practiceMar 2026
Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes.
Journal of diabetes investigationMar 2026
Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
semaglutidetirzepatideliraglutide
Obesity reviews : an official journal of the International Association for the Study of ObesityMar 2026
Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
JACC. Heart failureMar 2026
Get Weekly Research Updates
New clinical trials, study results, and plain-language summaries delivered to your inbox.
Free weekly newsletter · No spam, unsubscribe anytime